Genmab
GMAB
225 hedge funds and large institutions have $1.51B invested in Genmab in 2023 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 54 increasing their positions, 103 reducing their positions, and 46 closing their positions.
460% more call options, than puts
Call options by funds: $996K | Put options by funds: $178K
0.39% more ownership
Funds ownership: 71.83% → 72.22% (+0.39%)
7% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 46
3% less funds holding
Funds holding: 233 → 225 (-8)
10% less capital invested
Capital invested by funds: $1.67B → $1.51B (-$162M)
48% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 103
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$192M |
| 2 |
Morgan Stanley
New York
|
+$33.8M |
| 3 |
Millennium Management
New York
|
+$11.7M |
| 4 |
Renaissance Technologies
New York
|
+$10.1M |
| 5 |
AP
Antipodes Partners
Royal Exchange,
Australia
|
+$5.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$102M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$79.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$16.6M |
| 4 |
BlackRock
New York
|
-$12.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$8.18M |
GMAB Hedge Fund Activity: Q4 2023 in Review
225 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2023, worth a combined $1.51B — down 9.7% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of GMAB and 43 opened new positions — a net loss of 3 holders — while 103 trimmed existing stakes and 54 added.
The largest buyer was AllianceBernstein, adding an estimated $192M. The largest seller was Macquarie Group, cutting an estimated $102M.
- 225 institutional investors held Genmab (GMAB) as of Q4 2023, down from 233 in Q3 2023.
- Funds reported $1.51B of Genmab stock for Q4 2023, down 9.7% quarter-over-quarter.
- 43 funds opened new Genmab positions in Q4 2023 and 46 closed out, a net change of -3 holders.
- The largest Genmab buyer in Q4 2023 was AllianceBernstein, an estimated $192M added.
- The largest Genmab seller in Q4 2023 was Macquarie Group, an estimated $102M sold.
Based on aggregated 13F filings for Q4 2023.